Century Therapeutics, Inc.
IPSCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCentury Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Valued at $391.4M, IPSC is a small-cap name in its sector. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Market Cap
$391.4M
Beta
1.56
P/E (TTM)
—
P/E (Fwd)
-4.74
EPS (TTM)
$-1.14
EPS (Fwd)
$-0.46
ROE
-42.7%
ROA
-22.3%
Cash
$134.8M
Total Debt
$48.0M
Free CF
-$53.6M
52W Change
282.7%
Annual Financials
Cash vs Debt
Century Therapeutics, Inc. holds $134.8M in cash against $48.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$53.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -42.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $5.2M (2022) to $109.2M (2025), reflecting a 2000% increase over the period.
Century Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IPSC.